Johnson & Johnson (NYSE:JNJ) Shares Acquired by Diversified LLC

Diversified LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,702 shares of the company’s stock after buying an additional 928 shares during the period. Diversified LLC’s holdings in Johnson & Johnson were worth $1,126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Alliance Wealth Advisors LLC UT increased its stake in shares of Johnson & Johnson by 1.4% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock worth $739,000 after acquiring an additional 64 shares during the period. Carolinas Wealth Consulting LLC increased its stake in shares of Johnson & Johnson by 0.4% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after acquiring an additional 64 shares during the period. Epic Trust Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 3.6% during the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock worth $268,000 after acquiring an additional 64 shares during the period. Verity Asset Management Inc. increased its stake in shares of Johnson & Johnson by 2.0% during the fourth quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock worth $512,000 after acquiring an additional 65 shares during the period. Finally, Forza Wealth Management LLC increased its stake in shares of Johnson & Johnson by 0.8% during the second quarter. Forza Wealth Management LLC now owns 8,742 shares of the company’s stock worth $1,278,000 after acquiring an additional 66 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.1 %

NYSE:JNJ traded up $1.78 during trading hours on Friday, reaching $164.13. 7,093,429 shares of the company were exchanged, compared to its average volume of 7,299,449. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market cap of $395.01 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $167.78. The stock has a 50 day simple moving average of $153.92 and a 200 day simple moving average of $153.27.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.80 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.